Mp61-06 Survivin and Ki-67 Expression in Penile Squamous Cell Carcinoma: Clinicopathological Features and Outcomes

You have accessJournal of UrologyPenile & Testicular Cancer II (MP61)1 May 2024MP61-06 SURVIVIN AND KI-67 EXPRESSION IN PENILE SQUAMOUS CELL CARCINOMA: CLINICOPATHOLOGICAL FEATURES AND OUTCOMES Mateus W. De Bacco, Iago Z. Pires, Josenel M. Marçal, Mario B. Wagner, Andre P. Fay, and Gustavo F. Carvalhal Mateus W. De BaccoMateus W. De Bacco , Iago Z. PiresIago Z. Pires , Josenel M. MarçalJosenel M. Marçal , Mario B. WagnerMario B. Wagner , Andre P. FayAndre P. Fay , and Gustavo F. CarvalhalGustavo F. Carvalhal View All Author Informationhttps://doi.org/10.1097/01.JU.0001009536.58867.87.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Penile squamous cell carcinoma (PSCC) is endemic in Brazil and there are no useful biomarkers. Survivin and Ki-69 were correlated with worse prognosis and survival in a variety of neoplasms. We aimed to evaluate the expression of Survivin and Ki-67 in PSCC and its association with clinicopathological features and outcomes. METHODS: A retrospective cohort study was carried out from 1998 to 2016 in a tertiary hospital in Brazil using a convenience sample. Clinical characteristics, pathological features and outcomes were collected. Survivin and Ki-67 immunohistochemical expression were performed in formalin-fixed paraffin-embedded from PSCC. Survivin was considered positive with any staining in more than 5% of tumor and Ki-67 with any staining in more than 10%. Mann-Whitney U and Fisher's exact were used to analyze associations, and Kaplan-Meier curves with log-rank analysis for survival. RESULTS: Forty patients undergoing partial or total penectomy were selected. Five were excluded. Among 35 patients, 9 (25.7%) were Survivin positive (Survivin+), and 15 (42.8%) were Ki-67 positive. Survivin+ was more frequent in grade II and III than grade I (77.8% vs. 22.1), (p=0.027). Survivin+ patients were associated with worse survival (HR 3.73; CI95% 1.25–11.12; p=0.018). Expression of Ki-67 did not show a clear association with large lesions (p=0.055), high tumor grade (grade II and III 73.3% X 55% grade II for the Ki-67<10% group with p=0.062), or survival outcomes (HR 1.66; CI95% 0.56–4.98; p=0.362). CONCLUSIONS: Survivin expression appears to be promising in identifying patients with a worse prognosis and may be a pathway for more aggressive therapies in treatment of PSCC. Ki-67 expression does not appear to have impact on clinicopathological characteristics and overall survival. Source of Funding: None declared © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1012 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mateus W. De Bacco More articles by this author Iago Z. Pires More articles by this author Josenel M. Marçal More articles by this author Mario B. Wagner More articles by this author Andre P. Fay More articles by this author Gustavo F. Carvalhal More articles by this author Expand All Advertisement PDF downloadLoading ...